Nanobac Announces Peer Reviewed Publication Verifying Self-Propagating Calcifying Nanoparticles as a Unique Entity

TAMPA, FL ("Nanobac" or "the Company") announces the multicenter publication of independent research, which reports on the characterization of calcifying nanoparticles (CNPs), formerly known as "nanobacteria," as self-propagating mineral protein complexes. The study was led by a leading French microbiologist, the esteemed professor Didier Raoult (Raoult et al, PLoS Pathogens, February 2008, volume 4, issue 2).

The authors undertook a comprehensive analysis of CNPs utilizing a Nanobacterium strain provided by Nanobac's Chief Research and Science Officer Dr. Olavi Kajander. Their goal was to gain better insight into "such a propagating calcifying agent putatively endowed with pathogenic properties." To address this question, the researchers examined CNPs' propagation conditions, susceptibility to various chemical and physical treatments and their effect on cell viability. CNPs' nucleic acid and proteomic content were also analyzed.

Dr. Kajander stated: "The Raoult study confirms the presence of protein-mineral complexes, consistent with complexes published in Nanobac's Patent Applications, which characterized numerous proteins including fetuin, that the French group studied. The group also hypothesized the conformational change of the proteins being similar to those observed in prions, confirming our position. The study also confirmed that the Company's patented 8D10 antibody effectively detected CNPs as a unique pathogen."

"This work has significant diagnostic implications and supports our findings. The published paper should end discussion about whether CNPs exist, and shift the focus on what they really are and what role they play in various diseases," said Dr. Benedict Maniscalco, Co-Chairman and Chief Medical Officer of Nanobac Pharmaceuticals.

About Pathologic Calcific Diseases

Irregular calcium deposits are implicated in inflammatory diseases such as heart disease, prostatitis and arthritis, and stone forming diseases such as kidney and gall stones. The impact on the health care delivery system could be substantial given that billions of dollars are spent each year on treating diseases associated with CNPs. The company is well positioned to take advantage of numerous diagnostic and therapeutic opportunities in these sectors.

Nanobac Pharmaceuticals Inc. has moved its corporate office to 3000 Bayport Drive, Suite 910 Tampa, Florida 33607. The new phone number is 813 865-1125. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

Contact: Nanobac Pharmaceuticals, Tampa Brady Millican 813-865-1125 Email Contact

Nanobac Pharmaceuticals (CE) (USOTC:NNBP)
Historical Stock Chart
From Dec 2024 to Jan 2025